InvestmentJun 10, 2026, 04:30 PM
Nyxoah Secures $110M Financing to Accelerate Genio's US Launch
AI Summary
Nyxoah SA has completed $110 million in aggregate financings, consisting of a $95 million equity financing and an anticipated $15 million second tranche from its European Investment Bank loan. This capital infusion is earmarked to accelerate the U.S. commercial launch of its Genio system for Obstructive Sleep Apnea (OSA). The company aims to leverage this funding to drive U.S.-driven growth and long-term value creation, building on its initial commercial momentum in the U.S. with 40 sales representatives.
Key Highlights
- Nyxoah secured $110 million in aggregate financings.
- This includes $95 million from equity financing with strong insider participation.
- An additional $15 million is expected from the EIB loan by June 2026.
- Funds will accelerate U.S. commercialization of the Genio system.
- Company currently has 40 sales representatives in the U.S.
- Genio system received FDA approval in August 2025.
Price Impact
More from NYXH